Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Candel Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 0 | 12 | +12 |
| Shares | 0 | 4.88M | +4.88M |
| Value | $0 | $52.9M | +$52.9M |
New holders (12)
Institutions that held Candel Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| FMR LLC | 2,500,000 | $27.1M | 0.00% |
| Franklin Resources Inc | 1,125,000 | $12.2M | 0.00% |
| Sands Capital Ventures, LLC | 811,737 | $8.80M | 1.33% |
| Vanguard Group Inc | 213,580 | $2.31M | 0.00% |
| Woodline Partners LP | 100,000 | $1.08M | 0.02% |
| Caas Capital Management LP | 50,000 | $542.0K | 0.04% |
| State Street Corp | 26,600 | $288.0K | 0.00% |
| BlackRock Inc. | 22,326 | $242.0K | 0.00% |
| Geode Capital Management, LLC | 20,395 | $221.0K | 0.00% |
| Millennium Management LLC | 10,646 | $115.0K | 0.00% |
| UBS Group AG | 3,000 | $33.0K | 0.00% |
| Wells Fargo & Company | 1,054 | $12.0K | 0.00% |
Sold out (0)
Institutions that held Candel Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
None.